{
 "awd_id": "0419205",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "SBIR Phase I:     Semisynthetic Synthesis of Mutacin 1140",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Om P. Sahai",
 "awd_eff_date": "2004-07-01",
 "awd_exp_date": "2004-12-31",
 "tot_intn_awd_amt": 100000.0,
 "awd_amount": 100000.0,
 "awd_min_amd_letter_date": "2004-06-10",
 "awd_max_amd_letter_date": "2004-06-10",
 "awd_abstract_narration": "This Small Business Innovation Research (SBIR) Phase I project will develop new preparative strategies for the peptide antibiotic Mutacin 1140 and related derivatives. Current fermentation and synthetic routes are impractical. In-vitro testing suggests that Mutacin and its derivatives may work on drug-resistant bacterial strains. The peptide backbone of the antibiotic will be produced by cloning and expressing a 22mer artificial gene. The structure will then be modified to a range of derivatives synthetically.\r\n\r\nThe commercial application of the proposed project is in the area of antibiotics to combat human infectious diseases. Screening has indicated effectiveness against a wide range of gram positive and some gram-negative pathogens including multidrug resistant strains of Staphylococcus  aureus.\r\n",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Jeffrey",
   "pi_last_name": "Hillman",
   "pi_mid_init": "D",
   "pi_sufx_name": "",
   "pi_full_name": "Jeffrey D Hillman",
   "pi_email_addr": "jhillman@oragenics.com",
   "nsf_id": "000266701",
   "pi_start_date": "2004-06-10",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Oragenics Corporation",
  "inst_street_address": "4902 EISENHOWER BLVD STE 125",
  "inst_street_address_2": "",
  "inst_city_name": "TAMPA",
  "inst_state_code": "FL",
  "inst_state_name": "Florida",
  "inst_phone_num": "3864184018",
  "inst_zip_code": "336346342",
  "inst_country_name": "United States",
  "cong_dist_code": "14",
  "st_cong_dist_code": "FL14",
  "org_lgl_bus_name": "ORAGENICS, INC",
  "org_prnt_uei_num": "JVXASNXE8SR7",
  "org_uei_num": "JVXASNXE8SR7"
 },
 "perf_inst": {
  "perf_inst_name": "Oragenics Corporation",
  "perf_str_addr": "4902 EISENHOWER BLVD STE 125",
  "perf_city_name": "TAMPA",
  "perf_st_code": "FL",
  "perf_st_name": "Florida",
  "perf_zip_code": "336346342",
  "perf_ctry_code": "US",
  "perf_cong_dist": "14",
  "perf_st_cong_dist": "FL14",
  "perf_ctry_name": "",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537100",
   "pgm_ele_name": "SBIR Phase I"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "9107",
   "pgm_ref_txt": "BIOELECTRONICS AND BIONETWORKS"
  },
  {
   "pgm_ref_code": "BIOT",
   "pgm_ref_txt": "BIOTECHNOLOGY"
  }
 ],
 "app_fund": [
  {
   "app_code": "0104",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "490100",
   "fund_code": "app-0104",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2004,
   "fund_oblg_amt": 100000.0
  }
 ],
 "por": null
}